Cigna’s Evernorth just made a move to boost Humira biosimilar use

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) 

Cigna’s health ser­vices arm Ever­north said on Thurs­day that it plans to of­fer a cheap­er copy­cat of Ab­b­Vie’s block­buster drug Hu­mi­ra for $0, but it prob­a­bly won’t move the nee­dle on slow biosim­i­lar up­take.

The move comes af­ter Cigna’s ri­val CVS Health part­nered with drug­mak­er San­doz to sell a Hu­mi­ra biosim­i­lar and kicked the brand-name drug from its na­tion­al for­mu­la­ry.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.